Soleno Therapeutics, Inc. (SLNO)

37.89 +0.55 (+1.47%) At close: 04:00PM EDT

Soleno Therapeutics, Inc.

203 Redwood Shores Parkway
Suite 500
Redwood City, CA 94065
United States
650 213 8444
https://soleno.life

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 33

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Anish Bhatnagar M.D.	President, CEO, COO & Director	1.06M	N/A	1970
Mr. James H. MacKaness	Chief Financial Officer	640k	N/A	1964
Ms. Patricia C. Hirano	Senior Vice President of Regulatory Affairs	493k	N/A	1966
Ms. Lauren Budesheim	Vice President of People	N/A	N/A	N/A
Ms. Kristen Yen M.S.	Senior Vice President of Clinical Operations	317.19k	N/A	1969
Dr. Neil M. Cowen M.B.A., Ph.D.	Senior Vice President of Drug Development	N/A	N/A	N/A
Ms. Meredith Manning M.B.A.	Chief Commercial Officer	N/A	N/A	1972
Dr. Michael Huang M.D.	Senior Vice President of Clinical Development	N/A	N/A	1974

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Corporate governance

Soleno Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.